These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8117858)

  • 1. Use of finger-prick human blood samples as a more convenient way for in-vitro screening of modified hemoglobin blood substitutes for complement activation: a preliminary report.
    Chang TM; Lister CW
    Biomater Artif Cells Immobilization Biotechnol; 1993; 21(5):685-90. PubMed ID: 8117858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A screening test for modified hemoglobin blood substitutes before clinical use: based on C3a complement activation in human plasma.
    Chang TM; Lister C
    Biomater Artif Cells Artif Organs; 1990; 18(5):693-701. PubMed ID: 2099226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of blood substitutes: II. In-vitro complement activation of human plasma and blood for safety studies in research, development, industrial production and preclinical analysis.
    Chang TM; Lister CW
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(2):171-80. PubMed ID: 8087240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preclinical screening test for modified hemoglobin to bridge the gap between animal safety studies and use in human.
    Chang TM; Lister C
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):565-73. PubMed ID: 1391479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood substitutes based on modified hemoglobin prepared by encapsulation or crosslinking: an overview.
    Chang TM
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):159-79. PubMed ID: 1391433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of homologous and heterologous stroma-free hemoglobin and polyhemoglobin on complement activation, leucocytes and platelets.
    Ning J; Chang TM
    Biomater Artif Cells Artif Organs; 1990; 18(2):219-32. PubMed ID: 2369648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety studies of modified hemoglobin as an oxygen-carrying blood substitute.
    Chang TM
    Hematol Pathol; 1993; 7(1):49-55. PubMed ID: 8468266
    [No Abstract]   [Full Text] [Related]  

  • 8. Complement activation and the toxicity of stroma-free hemoglobin solutions in primates.
    Feola M; Simoni J; Dobke M; Canizaro PC
    Circ Shock; 1988 Aug; 25(4):275-90. PubMed ID: 3168173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1.
    Szebeni J; Wassef NM; Hartman KR; Rudolph AS; Alving CR
    Transfusion; 1997 Feb; 37(2):150-9. PubMed ID: 9051089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation.
    Pfeifer PH; Kawahara MS; Hugli TE
    Clin Chem; 1999 Aug; 45(8 Pt 1):1190-9. PubMed ID: 10430784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A convenient method for the determination of the solubility of hemoglobin and modified hemoglobins.
    Anderson PJ; Biro GP
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(3):753-61. PubMed ID: 7994398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple finger-prick method of screening for abnormal hemoglobins.
    Thambipillai S; Senewiratne B
    Am J Clin Pathol; 1975 Jun; 63(6):836-40. PubMed ID: 1146758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole complement hemolytic activity (CH50) following infusion of stroma-free and polyhemoglobin solutions in rats.
    Ning J; Chang TM
    Biomater Artif Cells Artif Organs; 1990; 18(2):203-17. PubMed ID: 2369647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: inhibition by soluble complement receptor type 1.
    Szebeni J; Spielberg H; Cliff RO; Wassef NM; Rudolph AS; Alving CR
    Artif Cells Blood Substit Immobil Biotechnol; 1997 Jul; 25(4):347-55. PubMed ID: 9242930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of complement factor C3 and its activated product, C3a, in operatively salvaged blood.
    Sieunarine K; Wetherall J; Lawrence-Brown MM; Goodman MA; Prendergast FJ; Hellings M
    Aust N Z J Surg; 1991 Apr; 61(4):302-5. PubMed ID: 2018440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemoglobin-based oxygen carriers do not alter platelet functions: study of three chemically modified hemoglobin solutions.
    Toussaint M; Latger-Cannard V; Caron A; Lecompte T; Vigneron C; Menu P
    Intensive Care Med; 2003 Jan; 29(1):62-8. PubMed ID: 12528024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality control of hemoglobin-based blood substitutes.
    Hsia JC; Er SS
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):105-11. PubMed ID: 3179461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct induction of complement activation by pharmacologic activation of plasminogen.
    Schaiff WT; Eisenberg PR
    Coron Artery Dis; 1997 Jan; 8(1):9-18. PubMed ID: 9101117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of complement by human hemoglobin and by mixtures of hemoglobin and bacterial endotoxin.
    Kaca W; Roth R
    Biochim Biophys Acta; 1995 Aug; 1245(1):49-56. PubMed ID: 7654765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemically modified and recombinant hemoglobin blood substitutes.
    Snyder SR; Walder JA
    Biotechnology; 1991; 19():101-16. PubMed ID: 1786467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.